Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes

NCT00727857 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00727857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00727857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
August 31, 2008
Enrollment
600 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus